( LUGANO Switzerland--(BUSINESS WIRE)--J...)Positive ZIO-201 Interim Phase II Sarcoma Data Presented at,European Society for Medical Oncology,Health

LUGANO, Switzerland--(BUSINESS WIRE)--Jul 9, 2007 - ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) announces that positive interim data from an ongoing phase II trial of ZIO-201 (isophosphoramide mustard - IPM) to treat advanced sarcoma patients was presented at the European Society of Medical Oncology (ESMO) meeting held July 5-8, 2007 in Lugano, Switzerland. The abstract entitled, "Phase-I/II Study of IPM (ZIO-201) In Advanced Sarcoma," was presented by Rashmi Chugh, MD, a Principal Investigator from the University of Michigan, Ann Arbor, Michigan.

The trial has now enrolled 39 patients and this presentation reports on the first 10 evaluable patients. Of these 10 heavily pretreated patients (median 4 prior regimens), 1 has a partial response (21 weeks and ongoing) and 4 have stable disease. Of these 5 patients, 2 had progressed through prior ifosfamide (IFOS) treatment. ZIO-201 was shown to be well tolerated at the phase II dose with no significant bone marrow suppression, alopecia (hair loss) or neurotoxicity reported. Based on this encouraging data, enrollment has been expanded to include additional patients.

"Ifosfamide is one of the few effective standard therapies available for most sarcomas," commented Dr. Chugh. "Having a novel drug that could offer the benefits of high-dose ifosfamide without the debilitating side effects, particularly the bone marrow suppression and neurotoxicity, would be of great benefit in the treatment of this disease. We are enthusiastic about these early results and we look forward to further elucidating the overall impact of ZIO-201 in this setting."

The Company expects to report more complete data at upcoming medical meetings, including the 14th European Cancer Conference (ECCO) taking place in Barcelona from September 23-27, 2007.

About ZIO-201

ZIO-201, the active moiety of IFOS, is a bi-functional alkylator that causes irreparable inter-strand DNA cross-
'"/>

Page: 1 2 3
Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Protox Announces Positive Clinical Data from Prostate Cancer Study
5. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
11. Alkermes Announces Positive Results from Phase 1/2 Clinical Study of ALKS 29